Amryt Pharma

company

About

Amryt Pharma is a pharmaceutical company.

  • 51 - 100

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
€20M
Industries
Medical,Pharmaceutical
Founded date
Jan 1, 2012
Number Of Employee
51 - 100
Operating Status
Active

Amryt Pharma is a specialty pharmaceutical company focused on the developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.

Amryt’s lead product, Episalvan, received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016. Amryt intends to further develop Episalvan as a new treatment for a hereditary skin disorder called Epidermolysis Bullosa in both Europe and the U.S.

Amryt’s earlier stage products are focussed on developing novel, next generation somatostatin analogue (“SSA”) peptide medicines for patients with rare neuroendocrine diseases, where there is high unmet medical needs. These include acromegaly and Cushing's disease.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
€20M
Amryt Pharma has raised a total of €20M in funding over 2 rounds. Their latest funding was raised on Dec 2, 2016 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 2, 2016 Post-IPO Debt €20M 1 European Investment Bank Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Amryt Pharma is funded by 1 investors. European Investment Bank are the most recent investors.
Investor Name Lead Investor Funding Round
European Investment Bank Yes Post-IPO Debt